Tweet
han 20 years ago and originally named ganoderic acids U, V, W, X, and Y, demonstrated cytotoxicity against hepatoma cells in vitro. More recently, ganoderic acids A and C inhibited
farnesyl protein transferase, an enzyme that is crucial for activation of the Ras oncoprotein responsible for cell transformation. Furthermore, new triterpenes isolated from the spores of Ganoderma lucidum were tested for their cytotoxicity against mouse sarcoma (Meth-A) and mouse Lewis lung carcinoma (LLC) cells. The ganoderic alcohols lucidimols
A and B, ganodermanondiol, ganoderiol F, and ganodermanontriol\ demonstrated cytotoxic effects on both tumor cell lines. However, the new isolated ganoderic acids ,, , , , and did not show any activity against cancer cells. The triterpenoid fraction of the fruiting body of Ganoderma lucidum inhibited primary solid-tumor growth in the spleen, liver metastasis, and secondary metastatic tumor growth in the liver, which were originally
induced by the intrasplenic implantation of the LLC in mice. In addition, the triterpenoid fraction inhibited Matrigel-induced neovascularization, and the biologically active compound responsible for the inhibition of angiogenesis was identified as ganoderic
acid F. Phenols isolated by the methanolic extraction from Ganoderma lucidum demonstrated antioxidant activity in the inhibition of lipid peroxidation, which was comparable to the antioxidant activity of phenols isolated from Ganoderma tsugae. Lipids extracted from the
germinating spores of Ganoderma lucidum remarkably inhibited the growth of mouse hepatoma, sarcoma S-180, and reticulocyte sarcoma L-II cells in mouse, suggesting
farnesyl protein transferase, an enzyme that is crucial for activation of the Ras oncoprotein responsible for cell transformation. Furthermore, new triterpenes isolated from the spores of Ganoderma lucidum were tested for their cytotoxicity against mouse sarcoma (Meth-A) and mouse Lewis lung carcinoma (LLC) cells. The ganoderic alcohols lucidimols
A and B, ganodermanondiol, ganoderiol F, and ganodermanontriol\ demonstrated cytotoxic effects on both tumor cell lines. However, the new isolated ganoderic acids ,, , , , and did not show any activity against cancer cells. The triterpenoid fraction of the fruiting body of Ganoderma lucidum inhibited primary solid-tumor growth in the spleen, liver metastasis, and secondary metastatic tumor growth in the liver, which were originally
induced by the intrasplenic implantation of the LLC in mice. In addition, the triterpenoid fraction inhibited Matrigel-induced neovascularization, and the biologically active compound responsible for the inhibition of angiogenesis was identified as ganoderic
acid F. Phenols isolated by the methanolic extraction from Ganoderma lucidum demonstrated antioxidant activity in the inhibition of lipid peroxidation, which was comparable to the antioxidant activity of phenols isolated from Ganoderma tsugae. Lipids extracted from the
germinating spores of Ganoderma lucidum remarkably inhibited the growth of mouse hepatoma, sarcoma S-180, and reticulocyte sarcoma L-II cells in mouse, suggesting
Comment